Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1971 Feb;47(544):116–119. doi: 10.1136/pgmj.47.544.116

L-Dopa and amantadine hydrochloride in extra-pyramidal disorders

J D Parkes, R P Knill-Jones, P J Clements
PMCID: PMC2467156  PMID: 5572526

Abstract

L-Dopa and amantadine hydrochloride were separately given to patients with diverse extra-pyramidal disorders including progressive supranuclear palsy; porto-systemic encephalopathy; oculogyric crises; drug-induced Parkinsonism; Huntington's chorea, hemiballismus; spasmodic torticollis, familial tremor; and athetosis. Akinesia and rigidity were improved in the first two conditions and simultaneously there was improvement in disordered eye movement. Amantadine provoked an exacerbation in spasmodic torticollis and familial tremor. No other condition was influenced. Both amantadine and L-dopa will facilitate eye movement mechanisms: it seems probable that both drugs act on dopamine-sensitive areas within the CNS. Neither drug will give significant benefit in the above disorders.

Full text

PDF
116

Images in this article

117Fig. 1
on p.117
117Fig. 2
on p.117

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., SPECTOR S., SHORE P. A. Interaction of drugs with norepinephrine in the brain. Pharmacol Rev. 1959 Jun;11(2 Pt 2):548–564. [PubMed] [Google Scholar]
  2. Barbeau A., Friesen H. Treatment of Wilson's disease with L-dopa after failure with penicillamine. Lancet. 1970 May 30;1(7657):1180–1181. doi: 10.1016/s0140-6736(70)91259-6. [DOI] [PubMed] [Google Scholar]
  3. Barbeau A. L-dopa and juvenile Huntington's disease. Lancet. 1969 Nov 15;2(7629):1066–1066. doi: 10.1016/s0140-6736(69)90662-x. [DOI] [PubMed] [Google Scholar]
  4. Behrman S., Carroll J. D., Janota I., Matthews W. B. Progressive supranuclear palsy. Clinico-pathological study of four cases. Brain. 1969;92(3):663–678. doi: 10.1093/brain/92.3.663. [DOI] [PubMed] [Google Scholar]
  5. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  6. Grelak R. P., Clark R., Stump J. M., Vernier V. G. Amantadine-dopamine interaction: possible mode of action in Parkinsonism. Science. 1970 Jul 10;169(3941):203–204. doi: 10.1126/science.169.3941.203. [DOI] [PubMed] [Google Scholar]
  7. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev. 1966 Jun;18(2):925–964. [PubMed] [Google Scholar]
  8. MCGEER P. L., BOULDING J. E., GIBSON W. C., FOULKES R. G. Drug-induced extrapyramidal reactions. Treatment with diphenhydramine hydrochloride and dihydroxyphenylalanine. JAMA. 1961 Sep 9;177:665–670. doi: 10.1001/jama.1961.03040360001001. [DOI] [PubMed] [Google Scholar]
  9. Mena I., Court J., Fuenzalida S., Papavasiliou P. S., Cotzias G. C. Modification of chronic manganese poisoning. Treatment with L-dopa or 5-OH tryptophane. N Engl J Med. 1970 Jan 1;282(1):5–10. doi: 10.1056/NEJM197001012820102. [DOI] [PubMed] [Google Scholar]
  10. Mendell J. R., Engel W. K., Chase T. N. Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism. Lancet. 1970 Mar 21;1(7647):593–594. doi: 10.1016/s0140-6736(70)91629-6. [DOI] [PubMed] [Google Scholar]
  11. Vernier V. G., Harmon J. B., Stump J. M., Lynes T. E., Marvel J. P., Smith D. H. The toxicologic and pharmacologic properties of amantadine hydrochloride. Toxicol Appl Pharmacol. 1969 Nov;15(3):642–665. doi: 10.1016/0041-008x(69)90066-0. [DOI] [PubMed] [Google Scholar]
  12. Victor M., Adams R. D., Cole M. The acquired (non-Wilsonian) type of chronic hepatocerebral degeneration. Medicine (Baltimore) 1965 Sep;44(5):345–396. doi: 10.1097/00005792-196509000-00001. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES